Cart
sales@molnova.com
Avacopan
CAS No. 1346623-17-3
Avacopan( CCX-168 | CCX168 )
Catalog No. M11405 CAS No. 1346623-17-3
Avacopan (CCX-168, CCX168) is a potent, selective, orally availale C5aR (CD88) inhibitor with IC50 of 0.1 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 81 | In Stock |
|
| 5MG | 133 | In Stock |
|
| 10MG | 212 | In Stock |
|
| 25MG | 422 | In Stock |
|
| 50MG | 606 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAvacopan
-
NoteResearch use only, not for human use.
-
Brief DescriptionAvacopan (CCX-168, CCX168) is a potent, selective, orally availale C5aR (CD88) inhibitor with IC50 of 0.1 nM.
-
DescriptionAvacopan (CCX-168, CCX168) is a potent, selective, orally availale C5aR (CD88) inhibitor with IC50 of 0.1 nM; shows no activity (IC50 >5,000 nM)for C5aR-related receptors C5L2, C3aR, ChemR23, GPR1 and FPR1; inhibits C5a-mediated chemotaxis of U937 cells with pA2 of 0.2 nM; shows activity in mouse model of ANCA-induced glomerulonephritis.Other Indication Phase 3 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsCCX-168 | CCX168
-
PathwayImmunology/Inflammation
-
TargetComplement System
-
RecptorComplement System
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1346623-17-3
-
Formula Weight581.656
-
Molecular FormulaC33H35F4N3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 10.1 mg/mL 17.36 mM; H2O : < 0.1 mg/mL
-
SMILESO=C([C@@H]1[C@H](C2=CC=C(NC3CCCC3)C=C2)N(C(C4=C(C)C=CC=C4F)=O)CCC1)NC5=CC=C(C)C(C(F)(F)F)=C5
-
Chemical Name(2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xiao H, et al. J Am Soc Nephrol. 2014 Feb;25(2):225-31.
2. Bekker P, et al. PLoS One. 2016 Oct 21;11(10):e0164646.
3. Jayne DRW, et al. J Am Soc Nephrol. 2017 Sep;28(9):2756-2767.
molnova catalog
related products
-
W-54011
A potent and orally active non-peptide C5a receptor (CD88;C5aR) antagonist with Ki of 2.2 nM.
-
Vesencumab
Vesencumab (MNRP-1685A) is an IG1 antibody targeting NRP-1 with anti-angiogenic and anti-tumor activity that reduces the number of globules formed by the SUM159 and Hs578T cell lines. Vesencumab inhibits EGFR and PDGFRα activation and can be used to study solid tumors.
-
BR111
BR111 is a potent, highly selective and orally active antagonist of complement C3a receptor (C3aR) with IC50 of 85?±?40 ?nM.
